Dr. Neil Smith reports

CANABO OPENS CLINIC IN LONDON, ONTARIO AND ANNOUNCES PLANS TO RELEASE ITS FIRST OBSERVATIONAL RESEARCH STUDY

Canabo Medical Inc. has opened its 15th clinic in London, Ont. The London clinic is located at 130 Thompson Rd.

Also, Dr. Neil Smith, executive chairman, will be presenting results from the company's observational study at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) cannabinoids in clinical practice event from April 6 to April 7, 2017, in Toronto. The research to be presented will focus on observations of benzodiazepine use among Canabo patients. The company currently tracks over 1,500 patients who started medical cannabinoids while on benzodiazepines.

Dr. Smith stated: "We consider the release of this first research report a milestone not just for Canabo but for the medical cannabis industry as a whole. We anticipate that the results of our first study will be significant within the medical community as a large number of patients under our treatments completely eliminated benzodiazepines from their medication regime." The study co-author team includes the following individuals.

Dr. Andrew Davis, PhD

Dr. Davis received his PhD and MA in economics from the University of Rochester, where he also held both a Sproull fellowship and a Lionel McKenzie fellowship, and a BSc from the Memorial University of Newfoundland. Dr. Davis has regularly presented research at a variety of seminars and conferences, including the Canadian Economics Association, of which he is a member, and is most recently published in Economic Modelling.

Dr. Danial Schecter, MD, CCFP

Dr. Schecter is co-founder of the Cannabinoid Medical Clinic (CMClinic) and a practising family physician. As a recognized medical expert in the field of prescription cannabinoids and medical marijuana, Dr. Schecter has given numerous presentations to fellow physicians and developed educational programs on this subject.

Dr. Michael Verbora, MBA, MD, CCFP

Dr. Verbora earned his medical degree at the University of Western Ontario and his master of business administration (MBA) from the Odette School of Business. To date, Dr. Verbora has completed over 2,000 initial consultations for cannabinoid therapy. He has also presented for the Ontario College of Family Physicians' annual Windsor pain conference on cannabinoid therapy. Dr. Verbora is a member of the CCIC, Doctors for Responsible Access (DRA) and the Canadian Pain Society (CPS).

Dr. Mark Taylor, MD, FRCS(C), FACS

Dr. Taylor is currently a professor as well as the interim head of the division of otolaryngology -- head and neck surgery -- at Dalhousie University. Dr. Taylor has 15 years of experience as a head and neck surgeon in Halifax in addition to resident education. His practice focuses on head and neck oncology, as well as facial plastic and reconstructive surgery, in which he is also board certified. Dr. Taylor has over 150 peer-reviewed publications to his credit and has a particular interest in research into cannabinoid therapy.

About Canabo Medical Inc.

Canabo wholly owns and operates 15 cannabinoid medical clinics, Canada's most respected and largest referral-only clinics for medical cannabis. Since beginning operations in 2014, Canabo now has clinic locations in Toronto, Barrie, St. Catharines, Burlington, Stoney Creek, Ottawa, Hamilton, London, Halifax, St. John's, Moncton, Kingston, Edmonton, Calgary and Chilliwack. The company plans to open an additional seven clinics in 2017.

We seek Safe Harbor.